Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA; Epilepsy Genetics Program, Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Boston, MA; Department of Pediatrics, Harvard Medical School, Boston, MA.
Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA; Department of Pediatrics, Harvard Medical School, Boston, MA.
Genet Med. 2022 Nov;24(11):2240-2248. doi: 10.1016/j.gim.2022.07.020. Epub 2022 Aug 23.
Postzygotic (somatic) variants in the mTOR pathway genes cause a spectrum of distinct developmental abnormalities. Accurate classification of somatic variants in this group of disorders is crucial for affected individuals and their families.
The ClinGen Brain Malformation Variant Curation Expert Panel was formed to curate somatic variants associated with developmental brain malformations. We selected the genes AKT3, MTOR, PIK3CA, and PIK3R2 as the first set of genes to provide additional specifications to the 2015 American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) sequence variant interpretation guidelines, which currently focus solely on germline variants.
A total of 24 of the original 28 ACMG/AMP criteria required modification. Several modifications used could be applied to other genes and disorders in which somatic variants play a role: 1) using variant allele fraction differences as evidence that somatic mutagenesis occurred as a proxy for de novo variation, 2) incorporating both somatic and germline evidence, and 3) delineating phenotype on the basis of variable tissue expression.
We have established a framework for rigorous interpretation of somatic mosaic variants, addressing issues unique to somatic variants that will be applicable to many genes and conditions.
mTOR 通路基因的合子后(体)变异导致一系列不同的发育异常。准确分类这组疾病中的体细胞变异对于受影响的个体及其家属至关重要。
ClinGen 脑畸形变异物临床评估专家小组成立,以评估与发育性脑畸形相关的体细胞变异物。我们选择 AKT3、MTOR、PIK3CA 和 PIK3R2 这 4 个基因作为第一批基因,为 2015 年美国医学遗传学与基因组学学院/分子病理学协会(ACMG/AMP)序列变异物解释指南提供额外的规范,该指南目前仅专注于种系变异物。
最初的 28 项 ACMG/AMP 标准中有 24 项需要修改。其中一些修改可以应用于其他涉及体细胞变异物起作用的基因和疾病:1)使用变异等位基因分数差异作为体细胞突变发生的证据,以替代新生变异,2)合并体细胞和种系证据,以及 3)根据可变组织表达来描绘表型。
我们已经建立了严格解释体细胞镶嵌变异物的框架,解决了体细胞变异物特有的问题,这些问题将适用于许多基因和疾病。